OBJECTIVE: To investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC). DESIGN: In vitro and in vivo cell models were developed to investigate the biological and molecular functions of GPX7 in OAC. RESULTS: Reconstitution of GPX7 in OAC cell lines, OE33 and FLO-1, significantly suppressed growth as shown by the growth curve, colony formation and EdU proliferation assays. Meanwhile, GPX7-expressing cells displayed significant impairment in G1/S progression and an increase in cell senescence. Concordant with the above functions, Western blot analysis displayed higher levels of p73, p27, p21 and p16 with a decrease in phosphorylated retinoblastoma protein (RB), indicating its increased tumour suppressor activities. On the contrary, knockdown of GPX7 in HET1A cells (an immortalised normal oesophageal cell line) rendered the cells growth advantage as indicated with a higher EdU rate, lower levels of p73, p27, p21 and p16 and an increase in phosphorylated RB. We confirmed the tumour suppressor function in vivo using GPX7-expressing OE33 cells in a mouse xenograft model. Pyrosequencing of the GPX7 promoter region (-162 to +138) demonstrated location-specific hypermethylation between +13 and +64 in OAC (69%, 54/78). This was significantly associated with the downregulation of GPX7 (p<0.01). Neither mutations in the coding exons of GPX7 nor DNA copy number losses were frequently present in the OAC examined (<5%). CONCLUSIONS: Our data suggest that GPX7 possesses tumour suppressor functions in OAC and is silenced by location-specific promoter DNA methylation.
OBJECTIVE: To investigate the potential tumour suppressor functions of glutathione peroxidase 7 (GPX7) and examine the interplay between epigenetic and genetic events in regulating its expression in oesophageal adenocarcinomas (OAC). DESIGN: In vitro and in vivo cell models were developed to investigate the biological and molecular functions of GPX7 in OAC. RESULTS: Reconstitution of GPX7 in OAC cell lines, OE33 and FLO-1, significantly suppressed growth as shown by the growth curve, colony formation and EdU proliferation assays. Meanwhile, GPX7-expressing cells displayed significant impairment in G1/S progression and an increase in cell senescence. Concordant with the above functions, Western blot analysis displayed higher levels of p73, p27, p21 and p16 with a decrease in phosphorylated retinoblastoma protein (RB), indicating its increased tumour suppressor activities. On the contrary, knockdown of GPX7 in HET1A cells (an immortalised normal oesophageal cell line) rendered the cells growth advantage as indicated with a higher EdU rate, lower levels of p73, p27, p21 and p16 and an increase in phosphorylated RB. We confirmed the tumour suppressor function in vivo using GPX7-expressing OE33 cells in a mouse xenograft model. Pyrosequencing of the GPX7 promoter region (-162 to +138) demonstrated location-specific hypermethylation between +13 and +64 in OAC (69%, 54/78). This was significantly associated with the downregulation of GPX7 (p<0.01). Neither mutations in the coding exons of GPX7 nor DNA copy number losses were frequently present in the OAC examined (<5%). CONCLUSIONS: Our data suggest that GPX7 possesses tumour suppressor functions in OAC and is silenced by location-specific promoter DNA methylation.
Entities:
Keywords:
CANCER; CELL CYCLE; GASTROINTESTINAL CANCER; OESOPHAGEAL CANCER
Authors: Mohammed Soutto; Dunfa Peng; Mohammad Razvi; Petra Ruemmele; Arndt Hartmann; Albert Roessner; Regine Schneider-Stock; Wael El-Rifai Journal: Cancer Date: 2010-09-01 Impact factor: 6.860
Authors: Jurjen J Boonstra; Ronald van Marion; David G Beer; Lin Lin; Paula Chaves; Catarina Ribeiro; A Dias Pereira; Lúcia Roque; S Jane Darnton; Nasser K Altorki; David S Schrump; David S Klimstra; Laura H Tang; James R Eshleman; Hector Alvarez; Yutaka Shimada; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens Journal: J Natl Cancer Inst Date: 2010-01-14 Impact factor: 13.506
Authors: Li Chen; Moli Huang; Jasmine Plummer; Jian Pan; Yan Yi Jiang; Qian Yang; Tiago Chedraoui Silva; Nicole Gull; Stephanie Chen; Ling Wen Ding; Omer An; Henry Yang; Yulan Cheng; Jonathan W Said; Ngan Doan; Winand Nm Dinjens; Kevin M Waters; Richard Tuli; Simon A Gayther; Samuel J Klempner; Benjamin P Berman; Stephen J Meltzer; De-Chen Lin; H Phillip Koeffler Journal: Gut Date: 2019-08-13 Impact factor: 23.059
Authors: John H Saunders; David Onion; Pamela Collier; Matthew S Dorrington; Richard H Argent; Philip A Clarke; Alex M Reece-Smith; Simon L Parsons; Anna M Grabowska Journal: Oncotarget Date: 2017-04-11
Authors: Marc Jan Bonder; Silva Kasela; Mart Kals; Riin Tamm; Kaie Lokk; Isabel Barragan; Wim A Buurman; Patrick Deelen; Jan-Willem Greve; Maxim Ivanov; Sander S Rensen; Jana V van Vliet-Ostaptchouk; Marcel G Wolfs; Jingyuan Fu; Marten H Hofker; Cisca Wijmenga; Alexandra Zhernakova; Magnus Ingelman-Sundberg; Lude Franke; Lili Milani Journal: BMC Genomics Date: 2014-10-04 Impact factor: 3.969